Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This study will assess efficacy and safety of intraseasonal specific short-term immunotherapy
with Depiquick® Birch in patients with allergic rhinitis and or rhinoconjunctivitis with or
without intermittent asthma that have a clinical relevant IgE-mediated allergic sensitization
against birch pollen. The term "intraseasonal" means that patients will start with
immunotherapy treatment during the birch pollen season, i.e. when the already experience
allergic symptoms.